Heart transplantation has become the treatment of choice for eligible patients with end-stage heart failure. In this Perspectives article, David Baran challenges the presupposed need for multidrug immunosuppression after transplantation, and draws on data and experience from the TICTAC randomized trial to explore the potential efficacy and benefits of monotherapy.